An observational study in Mitral Valve Regurgitation, sponsored by Fondazione GISE Onlus. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.
Sponsored by Fondazione GISE Onlus · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Mitral Valve Insufficiency with a site in Italy — 20 open to participants now, 28 under way, none of them phase 3. Mitral Valve Insufficiency · Italy.
Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, this one is the 13th largest by planned enrollment of the 33 observational ones that give a count, is one of 3 that started in 2023, is one of 33 observational ones, reaches primary completion later than 21 of the 27 other live ones, and was the 43rd registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →20 of the 63 studies in Mitral Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:
Centro Cardiologico Monzino · Sites in Italy
Ages 18+
ASL Città di Torino · Sites in Italy, Belgium
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Medical University of Vienna · Sites in Italy, Austria, Germany and 1 more country
Ages 18+
Fundación para la Investigación Biosanitaria del Principado de Asturias · Sites in Italy, Israel, Netherlands and 1 more country
Ages 18–99
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 264 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 95 across the 30 interventional studies, 200 across the 33 observational. Of the 24 that completed or were terminated, 7 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 63 have an industry lead sponsor. The 10 most frequent:
Fondazione GISE Onlus is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Fondazione GISE Onlus has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Mitral Valve Insufficiency with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07632794Mi ChenArtificial Intelligence Assisting Transcatheter Mitral Edge-to-Edge Repair | 2026-12-31 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06282042Fundación para la Investigación Biosanitaria del Principado de AsturiasEarly Transcatheter Mitral Valve Repair After Myocardial Infarction | 2027-06-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the GISE study is to confirm the MitraClip safety and improve the device effectiveness in a selected all comers ("more-comers") population with symptomatic severe mitral regurgitation undergoing/undergone Transcatheter Edge-to-Edge Repair (TEER) with MitraClip G4.
Patients undergoing/undergone to TEER procedure with MitraClip G4 in selected hospitals linked to the GISE network. Patients should meet all the inclusion criteria and none of the exclusion criteria; such criteria will identify a selected all comers ("more-comers") population which includes the vast majority of patients treated with MitraClip in daily practice. Retrospective enrolments are allowed if available data are in line with the study requirements and the patients can give their consent to be enrolled in the study informed consent process. Patients who don't meet one or more of the inclusion criteria or met at least one exclusion criteria are excluded from the study; however, a selected list of baseline/procedural features and follow-up data will be recorded for excluded patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SUBGROUP A: FUNCTIONAL MR Patients with symptomatic severe secondary MR (3-4+, according to the multiparametric study algorithm), both ischemic or non-ischemic etiology, on optimal medical therapy AND
THE MULTIPARAMETRIC ALGORITHM FOR MR GRADING The multiparametric algorithm, adapted from the criteria recommended by the American Society of Echocardiography 2003 Guidelines and based on 3 tiers of evaluation, will be used for qualification purposes to determine if MR was 3+ or higher. The 3 tiers of evaluation are applied in a hierarchical manner (from tier 1 to 3) and patients qualified for TEER by meeting the criteria of at least one of them. For MR grading purposes, MR severity was subsequently graded as 3+ or 4+ based on the integrative evaluation of multiple parameters recommended by the The American Society of Echocardiography (ASE)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with symptomatic severe secondary MR (3-4+, according to the multiparametric study algorithm), both ischemic or non-ischemic etiology, on optimal medical therapy
Patients with symptomatic severe primary MR (3-4+, according to the multiparametric study algorithm)
percentage of participants with a mitral regurgitation (MR)
grade ≤1+. Two separates subgroups will be identified according to the presence of functional (FMR) or degenerative (DMR) mitral valve disease.
Time frame: at 30 days
percentage of participants with a mitral regurgitation (MR)
grade ≤1+. Two separates subgroups will be identified according to the presence of functional (FMR) or degenerative (DMR) mitral valve disease.
Time frame: at 1 year
composite of all-cause death and hospitalization for heart failure (HF),
all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,
Time frame: at 30 days
composite of all-cause death and hospitalization for heart failure (HF),
all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,
Time frame: at 1 year
composite of all-cause death and hospitalization for heart failure (HF),
all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,
Time frame: at 2 years
composite of all-cause death and hospitalization for heart failure (HF),
all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,
Time frame: at 3 years
composite of all-cause death and hospitalization for heart failure (HF),
all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,
Time frame: at 4 years
composite of all-cause death and hospitalization for heart failure (HF),
all-cause death, cardiovascular death and non-cardiovascular death, myocardial infarction, hospitalizations for HF,
Time frame: at 5 years
Started Jan 2023 (actual). Primary completion is estimated for Aug 2029, 78 months after the start.
Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 78 months is above that.
Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione GISE Onlus